Namodenoson’s Favorable Safety Profile and Broad Patent Portfolio Positions it as a Promising Candidate in the Growing Obesity Treatment Market ...

Can-Fite BioPharma ( (CANF) ) just unveiled an update.

Can-Fite Biopharma Ltd. ADR Annual stock financials by MarketWatch. View the latest CANF financial statements, income statements and financial ratios.

The average one-year price target for Can-Fite BioPharma - Depositary Receipt (NYSEAM:CANF) has been revised to $3.46 / share. This is a decrease of 17.42% from the prior estimate of $4.19 dated ...

The latest update is out from Can-Fite BioPharma ( (CANF)). On December 26, 2025, Can-Fite BioPharma announced that Brazil’s patent office granted a patent protecting the use of its A3 adenosine ...

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...

Can-Fite BioPharma ( (CANF)) has issued an announcement. On December 23, 2025, Can-Fite BioPharma announced that, following shareholder approval on November 10, 2025, its board authorized a ...

Can Fite Biofarma (CANF) is scheduled to report earnings on February 3, 2026. The last reported earnings were for reported on April 14, 2025 for FY. The Actual Revenue was $674K, which beat the ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.